{"contentid": 488120, "importid": NaN, "name": "Russia to speed registration of new drugs; favoring domestic drugmakers", "introduction": "Russian Deputy Prime Minister Tatyana Golikova \u00e2\u0080\u0093 a state official also responsible for the development of pharmaceutical and healthcare sector in the Russian government - has instructed the national government to speed the procedure for registration of new drugs in Russia and to provide additional preferences to domestic drugmakers during public procurements, according to recent statements by the state press-service and some local media, reports The Pharma Letter\u00e2\u0080\u0099s local correspondent.", "content": "<p>Russian Deputy Prime Minister Tatyana Golikova &ndash; a state official also responsible for the development of pharmaceutical and healthcare sector in the Russian government - has instructed the national government to speed the procedure for registration of new drugs in Russia and to provide additional preferences to domestic drugmakers during public procurements, according to recent statements by the state press-service and some local media, reports The Pharma Letter&rsquo;s local correspondent.&nbsp;</p>\n<p>In accordance with the initiative, registration of drugs will be conducted on the basis of their pre-clinical studies (ie, animal tests) and a summary report of their safety and efficacy.&nbsp;</p>\n<p>In fact, temporary preferences for producers were introduced in 2020 and were primarily applied for drugs against COVID-19.&nbsp;</p>\n<h2><strong>Scheme already used, as for Sputnik V approval</strong></h2>\n<p>Such scheme has already been applied for registration of Sputnik V COVID-19 vaccine as well as favipiravir, which is a drug, recommended in Russia for the treatment of the novel coronavirus.&nbsp;</p>\n<p>This is not a single initiative, which was put forward by the state. As part of its plans is providing additional preferences for producers that develop a full-cycle production within the territory of Russia and other countries of the Eurasian Economic Union. Most of such producers will receive additional benefits during public procurements in the Russian market.&nbsp;</p>\n<p>Implementation of these plans is considered as very important by the Russian government as, according to press-service of the Russian Ministry of Industry and Trade, from the beginning of 2021, for a significant part of 215 drugs, which have the status of vital in Russia, there was a lack of production of active ingredients and finished dosage forms.&nbsp;</p>\n<p>Currently the so-called &ldquo;extra third&rdquo; rule, (which does not allow a foreign drug manufacturer to bid if at least two producers from the EAEU countries enter the auctions) already exists in Russia.</p>\n<p>Some local analysts believe the latest state proposals will create additional obstacles for foreign pharmaceutical companies during state tenders in Russia.&nbsp;</p>\n<p>In the meantime, most Russian pharmaceutical manufacturers and distributors also opposed the latest state initiatives as, according to them, there are only a few pharmaceutical companies in Russia that operate on a full cycle basis, and it is unclear why such preferences should be provided to them.</p>", "date": "2021-03-23 11:29:00", "meta_title": "Russia to speed registration of new drugs; favoring domestic drugmaker", "meta_keywords": "Registration, New drugs, Procedure, Speeding-up, Preferences, Domestic drugmakers", "meta_description": "Russia to speed registration of new drugs; favoring domestic drugmakers", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-23 11:28:07", "updated": "2021-03-23 11:34:21", "access": NaN, "url": "https://www.thepharmaletter.com/article/russia-to-speed-registration-of-new-drugs-favoring-domestic-drugmakers", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "russia_li.jpg", "image2id": "russia_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "All therapy areas", "topic_tag": "Focus On, From our correspondent, Government Affairs, In Depth, Regulation", "geography_tag": "Russia", "company_tag": NaN, "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-23 11:29:00"}